Imlifidase, an IgG-destroying enzyme, could receive FDA approval in the second half of 2026 and hit peak sales of $306 ...
Arguably the most well-known SERD is AstraZeneca’s Faslodex, which was approved in 2002 for breast cancer and is administered ...
Companies that have broken ground on or are actively constructing manufacturing facilities in the U.S. are exempted from the ...
Though details remain scant, the pending order is expected to be the latest effort in President Donald Trump's campaign to ...
The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback